MedTrace Logo

Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma

NCT00327808 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2012-12-03

No results posted yet for this study

Summary

The investigators will look at TPI-1020 safety and tolerability in mild to moderate asthmatic smoker subjects.

Conditions

Interventions

DRUG

TPI-1020

600 mcg BID x 14 days followed by 1200 mcg BID x 7 days

DRUG

budesonide

400 mcg BID x 14 days then 800 mcg/day x 7 more days

Sponsors & Collaborators

  • Syntara

    lead INDUSTRY

Principal Investigators

  • Paolo Renzi, MD · Syntara

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00327808 on ClinicalTrials.gov